Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
The purpose of the study is to determine whether the combination of Daclatasvir (DCV),
 Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C
 virus.
Allocation:

 Initial Therapy: Randomized Controlled Trial: Participants are assigned to intervention
 groups by chance

 Rescue Therapy: Nonrandomized Trial: Participants are expressly assigned to intervention
 groups through a non-random method such as physician choice

 Number of Arms:

 Initial Therapy: 2 Groups

 Rescue Therapy: 2 Groups
For more information regarding BMS clinical trial participation, please visit
 www.BMSStudyConnect.com.

 Inclusion Criteria:

 -  Males and Females ≥18 years of age, inclusive

 -  Chronic HCV infection Genotype 1 only

 -  Non-cirrhotic

 -  Treatment naive subjects with no previous exposure to an Interferon formulation (ie,
 IFNα, pegIFNα), ribavirin (RBV) or HCV Direct Acting Antiviral (DAA) (protease,
 polymerase inhibitor, etc.)

 Exclusion Criteria:

 -  HCV Genotype other than Genotype 1

 -  Documented or suspected hepatocellular carcinoma

 -  Evidence of decompensated liver disease

 -  Contraindication(s) to Peg/RBV therapy